Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
about
Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical IssuesEmerging Tools for Stroke Prevention in Atrial FibrillationDirect oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced ageDirect-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis.Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis.Anticoagulation in Atrial Fibrillation - Current ConceptsCardiovascular Pharmacogenomics--Implications for Patients With CKD.The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies.Considerations for Systemic Anticoagulation in ESRD.Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients.A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis.Antithrombotic medications in dialysis patients: a double-edged sword.Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program.Filtering Out Use of DOACs in Hemodialysis.Direct oral anticoagulant considerations in solid organ transplantation: A review.Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.Antithrombotic therapy in end-stage renal disease.Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry.Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1.Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes.The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.Defibrillation Testing During ICD Implantation - Should we or Should we Not?Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation.Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.Italian intersociety consensus on DOAC use in internal medicine.[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].[Catheter-based closure of the left atrial appendage : Stroke prevention in atrial fibrillation].Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study
P2860
Q26750767-46E37978-03B1-4556-AEC1-560FA1115B1FQ26765023-CDEBFCD3-D9CD-4F21-A2D7-F6899ECC92F4Q28079930-FAD79C7D-C08A-49F2-9C61-F557C5947578Q34670808-61C76FD8-9F93-4116-943F-7C4B01F17C0DQ35683869-A81AD45C-B030-4074-9AAE-40FDED29457AQ36069462-B34068C6-E2D6-4281-A63F-7031AD039CDDQ36171135-C2267A87-67FA-4557-997F-789DF7FC799AQ36458853-5D18B5D4-E390-44AD-81A4-2E45301D3232Q36696635-4AACA39B-BC14-4444-B995-70570D9E7D98Q37030683-FCF2BBB4-4D7D-4F87-A1F0-E872B43A1FBAQ38464975-7FF8B1A8-87BD-410A-BE2B-4A7D0CF3F6BAQ38665579-5A5A774F-1970-48F9-B5BE-44675AB93ACCQ38723869-D2278A30-AB08-423B-8D42-20A90F29B930Q38735704-9138B8DB-A3F1-4F33-BA02-AD3347935A69Q38801820-57A237DB-49A0-4BE6-A9F0-76DA60235251Q38812464-E858BA9D-8C72-4088-9EA0-4CC933418D41Q38821650-EE1E3278-8695-4A54-9188-2053527104C4Q38851354-0893A417-18B3-4EDE-AC00-E30581F8665CQ38918821-3F64F94F-79B7-4AE7-BA3E-C81CDA6CA5D8Q38992769-0E6689F6-0A01-4C5C-A773-DF86CE01348DQ39003917-72E42DF0-FA0E-40F8-A10C-E960B9504AEEQ39012313-1550185E-C316-468B-9C38-573261FCDB69Q39217774-302970D4-94BF-43C6-8B62-CEB13F9A6A13Q39329927-4CC55E83-215F-4FF1-8B6D-FE023DED61ACQ39923394-9FF4014E-DE8B-41B5-B3FB-07D8BEE67111Q41341319-813B6AFC-4165-4053-9B18-BA5BF70FA476Q44928316-6C5F86F0-FDEF-4C5E-854D-1D8CD7C02BB3Q45974877-FDAC983A-1B52-4D16-B68C-E005E5AE962FQ46042485-68564703-6905-4ED5-8109-67FD1A0A9EB4Q47106586-EEEF158A-E089-4AB7-8FF0-040FD8D52023Q47118947-506E9231-50B9-4C67-86BA-9103677CF0FBQ47148139-15078CCF-6065-4767-B5C9-B3A50467DDF8Q47365787-452CA234-EC37-42D1-ACB3-F8FD5084D515Q49647319-08D4880C-9B7C-4B75-A454-3F7DDD19FD40Q50002162-7B7F8112-E6B1-4BF1-89CA-E1F39696EF17Q50896785-81A52A37-3372-4F3C-9BF5-8980DB99D223Q52840065-4A4BDFFB-75AB-4843-BCA3-CAEBF58A70BAQ52848552-C5FCF186-B195-4A89-AB9D-0130BA8C8F66Q53140080-3B688F9A-2469-4333-B3BC-E24342C9C977Q57625963-6725FD8D-82A5-471E-8FC8-31C0772AAA96
P2860
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@ast
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@en
type
label
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@ast
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@en
prefLabel
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@ast
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@en
P2093
P2860
P1433
P1476
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
@en
P2093
Elazer R Edelman
Julia B Wenger
Kevin E Chan
Ravi I Thadhani
P2860
P304
P356
10.1161/CIRCULATIONAHA.114.014113
P407
P577
2015-01-16T00:00:00Z